Introduction {#H1-1-ZOI190234}
============

Inherited retinal degenerations are a heterogeneous group of disorders that lead to the progressive degeneration of photoreceptors and loss of vision. On the more severe end of the spectrum lie cone-rod dystrophies, in which there is preferential involvement of the central retina with early manifestations of cone-driven symptoms, including photophobia, dyschromatopsia, reduced visual acuity, and central scotomas. As the disease progresses, there is variable involvement of rods, affecting peripheral and night vision.

Prominin 1 (*PROM1*; OMIM [604365](http://omim.org/604365)) is commonly associated with cone-rod dystrophies.^[@zoi190234r1]^ However, throughout the literature, variations in *PROM1* have been implicated in extremely varied and overlapping phenotypes that have been described as retinitis pigmentosa^[@zoi190234r2],[@zoi190234r3],[@zoi190234r4],[@zoi190234r5],[@zoi190234r6],[@zoi190234r7],[@zoi190234r8]^; retinitis pigmentosa with macular involvement^[@zoi190234r9]^; retinal dystrophy^[@zoi190234r8]^; cone-rod dystrophy^[@zoi190234r1],[@zoi190234r8],[@zoi190234r10],[@zoi190234r11],[@zoi190234r12],[@zoi190234r13],[@zoi190234r14],[@zoi190234r15],[@zoi190234r16],[@zoi190234r17]^; bull's-eye maculopathy^[@zoi190234r18]^; bull's-eye maculopathy associated with rod, rod-cone, and macular dystrophy^[@zoi190234r19]^; Stargardt-like disease^[@zoi190234r20],[@zoi190234r21],[@zoi190234r22],[@zoi190234r23]^; macular dystrophy^[@zoi190234r24]^; and maculopathy with rod-cone dystrophy.^[@zoi190234r25]^ The age at onset, presenting symptoms, and severity of disease vary with sequence variations. Moreover, variants can be inherited in recessive and dominant fashions.^[@zoi190234r15]^

Despite many genetic reports that focus on identifying *PROM1* variants, the genotype-phenotype correlation remains poorly understood. In addition, the molecular roles of these sequence variations and their effects on protein function are largely unknown. Moreover, it remains unclear if *PROM1* has a more important role in cone or rod photoreceptors and how variants in the same gene can have a recessive and/or dominant effect. The aim of this study is to analyze the sequence variations in the *PROM1* gene in a series of patients to understand better their potential for pathophysiological consequences on retinal degeneration. This has important implications in the development of potential gene-based therapies and optogenetics for this complex genetic condition, especially as the successful treatment of macular photoreceptors could be sufficient to preserve good visual acuity in affected individuals.

Methods {#H1-2-ZOI190234}
=======

Clinical Assessment and Imaging {#H2-1-ZOI190234}
-------------------------------

The study design adhered to the tenets of the Declaration of Helsinki.^[@zoi190234r26]^ This study follows the [reporting guideline](http://www.ajo.com/article/S0002-9394(10)00690-2/fulltext) for case series. Institutional review boards at Oxford University Hospitals and the University of Bonn approved the studies, and patients provided written informed consent.

Patients were identified from genetic databases between July 1, 2014, and May 1, 2018, at 2 clinical genetic centers in Oxford, United Kingdom, and Bonn, Germany. The data analysis was conducted from May 1, 2018, to December 1, 2018. Medical records of patients with *PROM1*variants were reviewed for information on family, general history, and ophthalmic history. Details of clinical assessments, including visual acuity and dilated fundal examinations, were collected. Retinal imaging studies, including color photography, fundus autofluorescence (55° and 30°), and optical coherence tomography, were taken with the Heidelberg Spectralis system (Heidelberg Engineering). In addition, widefield fundus imaging was performed with the Optos 200Tx confocal scanning laser ophthalmoscopy camera (Optos).

Genetic Analysis {#H2-2-ZOI190234}
----------------

Sequence variations in *PROM1* were identified by targeted next-generation sequencing techniques. For patients at the Oxford site, enrichment for *PROM1* was achieved as part of a customized HaloPlex enrichment system kit (Agilent Technologies) designed to capture the coding exons and 10 base pairs of the flanking introns of 117 retinal genes. HaloPlex reactions were prepared per manufacturer's instructions. Libraries were pooled into batches of 14 and sequenced on an Illumina MiSeq instrument (Illumina) using a MiSeq version 3 kit per manufacturer's instructions. Reads were aligned using Burrows-Wheeler Aligner 2,^[@zoi190234r27]^ and variants were called using Platypus.^[@zoi190234r28]^ All variants identified by next-generation sequencing were confirmed by Sanger sequencing. For patients at the Bonn site, the next-generation sequencing methodology was performed as described previously.^[@zoi190234r1]^

Sequence variations were assessed for pathogenic association with protein function based on in silico analysis using Alamut Visual (Alamut Interactive Biosoftware). Nonsense variants and frameshift variants were considered pathogenic unless at the 3′ end of the gene. The likely pathogenicity of missense variants was crosschecked against the PolyPhen-2, SIFT, and Grantham matrix (for those variants that led to a stop codon) algorithm scores. The allelic frequency of variants was evaluated in gnomAD, which includes the Exome Aggregation Consortium data set. Geneious bioinformatics software version 11.1.5 (Geneious) was used for the *PROM1* nucleotide sequence analysis and mapping of specific variants to protein domains. For patients with autosomal recessive inheritance patterns and compound heterozygous variants (6 of 13 patients \[46%\]), no further genotyping analysis was carried out in individuals' parents to exclude the rare possibility that the 2 variants were present on the same chromosome.

Results {#H1-3-ZOI190234}
=======

Overall, 19 patients (13 \[68%\] women) aged 11 to 70 years were included in this study. Inheritance was autosomal recessive in 13 patients (68%) and autosomal dominant in 6 patients (32%). Ethnic origins included 11 British patients (58%), 5 German patients (26%), 2 Turkish patients (11%), and 1 Ukrainian patient (5%). Details of participant demographic characteristics, history, clinical findings, and genotype analysis are summarized in the [Table](#zoi190234t1){ref-type="table"}. Most participants (17 \[89%\]) were unrelated, except AD4 and AD5, who are related.

###### Demographic Characteristics and Phenotype-Genotype Correlation in Patients With *PROM1* Variants

  Patient[^**a**^](#zoi190234t1n1){ref-type="table-fn"}   Sex                    Age, y              Age at Onset, y   Presenting Symptoms (Duration of Symptoms, y)    Visual Acuity, logMAR   Severity of Phenotype                Other Ophthalmic Features                                  Genotype                *PROM1* Variant(s)                                       Predicted Amino Acid Sequence Change(s)   Variant Effect(s)
  ------------------------------------------------------- ---------------------- ------------------- ----------------- ------------------------------------------------ ----------------------- ------------------------------------ ---------------------------------------------------------- ----------------------- -------------------------------------------------------- ----------------------------------------- -------------------
  AR1                                                     F                      60s                 20                Photophobia, central visual loss (44)            HM OD; LP OS            Severe panretinal dystrophy          Cataract in RE; IOL in LE                                  Compound heterozygous   c.1557C\>A                                               p.Tyr519\*                                Nonsense
  c.1177_1178delAT                                        p.Ile393Argfs\*21      Frameshift                                                                                                                                                                                                                                                                                                                                
  AR2                                                     M                      50s                 12                Photophobia, central visual loss (40)            HM OU                   Severe panretinal dystrophy          Oscillopsia; cataract in RE; IOL in LE                     Compound heterozygous   c.1354_1355insT                                          p.Tyr452Leufs\*13                         Frameshift
  c.22del[^b^](#zoi190234t1n2){ref-type="table-fn"}       p.Leu8fs\*             Frameshift                                                                                                                                                                                                                                                                                                                                
  AR3                                                     F                      50s                 14                Central visual loss (40)                         LP OU                   Severe panretinal dystrophy          Nystagmus; IOL and retinal implant in RE; cataract in LE   Compound heterozygous   c.1354_1355insT                                          p.Tyr452Leufs\*13                         Frameshift
  c.436C\>T                                               p.Arg146\*             Nonsense                                                                                                                                                                                                                                                                                                                                  
  AR4                                                     M                      50s                 8                 Photophobia, central visual loss (44)            LP OU                   Severe panretinal dystrophy          PSCLO in BE                                                Compound heterozygous   c.1354_1355insT                                          p.Tyr452Leufs\*13                         Frameshift
  c.1557C\>A                                              p.Tyr519\*             Nonsense                                                                                                                                                                                                                                                                                                                                  
  AR5                                                     F                      40s                 6                 Central visual loss (41)                         1.6 OD; 1.4 OS          Severe panretinal dystrophy          Myopia; nystagmus; PSCLO in BE                             Homozygous              c.1354_1355insT                                          p.Tyr452Leufs\*13                         Frameshift
  AR6                                                     M                      20s                 Childhood         Central visual loss, scotoma (\>20)              1.3 OD; 1.3 OS          Severe panretinal dystrophy          Myopia; nystagmus                                          Homozygous              c.199C\>T                                                p.Gln67\*                                 Nonsense
  AR7                                                     F                      30s                 16                Photophobia, daylight vision problems (22)       HM OU                   Severe panretinal dystrophy          Cataract in RE; IOL in LE                                  Compound heterozygous   c.1301+2T\>C[^b^](#zoi190234t1n2){ref-type="table-fn"}   Splice donor site                         Aberrant splicing
  c.1767G\>A[^b^](#zoi190234t1n2){ref-type="table-fn"}    Splice donor site      Aberrant splicing                                                                                                                                                                                                                                                                                                                         
  AR8                                                     M                      50s                 28                Central visual loss, slow dark adaptation (30)   LP OU                   Severe panretinal dystrophy          None                                                       Homozygous              c.1579-1G\>C                                             Splice acceptor site                      Aberrant splicing
  AR9                                                     F                      20s                 18                Central visual loss (7)                          1.7 OD; 1.6 OS          Severe panretinal dystrophy          Myopia; nystagmus; PSCLO in BE                             Homozygous              c.1142-1G\>A                                             Splice acceptor site                      Aberrant splicing
  AR10                                                    F                      20s                 Childhood         Central visual loss, nyctalopia (\>20)           LP OU                   Severe panretinal dystrophy          Myopia; PSCLO in BE                                        Homozygous              c.1853T\>G                                               p.Leu618Arg                               Missense
  AR11                                                    F                      \<18                Childhood         Central visual loss (\>5)                        0.2 OD; 0.3 OS          Mild panretinal dystrophy            Strabismus in LE                                           Homozygous              c.1142-1G\>A                                             Splice acceptor site                      Aberrant splicing
  AR12                                                    F                      30s                 Childhood         Central visual loss (\>25)                       CF OU                   Severe panretinal dystrophy          None                                                       Compound heterozygous   c.1354_1355insT                                          p.Tyr452Leufs\*13                         Frameshift
  c.1142-1G\>A                                            Splice acceptor site   Aberrant splicing                                                                                                                                                                                                                                                                                                                         
  AR13                                                    M                      60s                 40                Central visual loss (20)                         CF OD; 0.2 OS           Moderate macular dystrophy           None                                                       Homozygous              c.1354_1355insT                                          p.Tyr452Leufs\*13                         Frameshift
  AD1                                                     F                      70s                 55                Central visual loss, scotoma (25)                1.0 OD; 0.0 OS          Mild to moderate macular dystrophy   None                                                       Heterozygous            c.1117C\>T                                               p.Arg373Cys                               Missense
  AD2                                                     M                      50s                 40                Photophobia, central visual loss (14)            0.2 OD; 0.6 OS          Mild macular dystrophy               None                                                       Heterozygous            c.1117C\>T                                               p.Arg373Cys                               Missense
  AD3                                                     F                      50s                 42                Photophobia, central visual loss (10)            0.4 OU                  Mild macular dystrophy               None                                                       Heterozygous            c.1117C\>T                                               p.Arg373Cys                               Missense
  AD4                                                     F                      50s                 41                Central visual loss (12)                         1.0 OU                  Moderate macular dystrophy           None                                                       Heterozygous            c.1117C\>T                                               p.Arg373Cys                               Missense
  AD5                                                     F                      30s                 29                Central visual loss, scotoma (2)                 0.1 OD; 0.0 OS          Mild macular dystrophy               None                                                       Heterozygous            c.1117C\>T                                               p.Arg373Cys                               Missense
  AD6                                                     F                      30s                 25                Central visual loss, scotoma (5)                 1.00 OD; 0.8 OS         Mild macular dystrophy               None                                                       Heterozygous            c.1117C\>T                                               p.Arg373Cys                               Missense

Abbreviations: AD, autosomal dominant; AR, autosomal recessive; BE, both eyes; CF, counting fingers; F, female; HM, hand movements; IOL, intraocular lens implant; LE, left eye; LP, light perception; M, male; PSCLO, posterior subcapsular lens opacity; RE, right eye.

First 2 letters of ID indicate variant inheritance pattern (recessive or dominant).

Previously unreported variant.

The clinical phenotypes of recessive and dominant variant classes are shown in [Figure 1](#zoi190234f1){ref-type="fig"}. Independent of variant class (ie, nonsense, frameshift, splice site, and missense), recessive genotypes showed severe panretinal dystrophy with macular involvement and peripheral pigment spicules. Fundus autofluorescence showed areas of macular hypoautofluorescence with variable degrees of patchier hypoautofluorescence patterns in the periphery. Optical coherence tomography revealed widespread loss or thinning of the outer retina in all recessive genotypes. In contrast, at a comparable age, the dominant genotype showed much milder changes, largely restricted to the macula on fundus autofluorescence and optical coherence tomography imaging, and no peripheral bone spicule pigmentations.

![Representative Images of *PROM1-*Related Retinal Degeneration Associated With Recessive and Dominant Genotypes\
From left to right, images are color photographs, fundus autofluorescence photographs, and optical coherence tomography images. A, Images of patient AR6; visual acuity, 1.3 OD and 1.3 OS; c.199C\>T variant. B, Images of patient AR5; visual acuity, 1.6 OD and 1.4 OS; c.1354dup variant. C, Images of patient AR9; visual acuity, 1.7 OD and 1.6 OS; c.1142-1G\>A variant. D, Images of patient AR10; visual acuity, light perception in both eyes; c.1853T\>G variant. E, Images of patient AD5; visual acuity, 0.1 OD and 0.0 OR; c.1117C\>T variant.](jamanetwopen-2-e195752-g001){#zoi190234f1}

The age at onset of retinal degeneration ranged from early childhood (recessive genotype) to 40 years (dominant genotype), with all patients presenting with central visual loss, indicating early cone involvement. Photophobia was present in 6 patients (32%) with recessive and dominant genotypes. The association of visual acuity with patient age is depicted in [Figure 2](#zoi190234f2){ref-type="fig"} and eTable 1 in the [Supplement](#note-ZOI190234-1-s){ref-type="supplementary-material"}, both of which include, to our knowledge, all *PROM1* cases reported with sufficient data to date. There is a decline in visual acuity in recessive variants from an early age, with visual acuity of 1.0 logMAR (Snellen equivalent, 20/200) or less in patients older than 20 years, and most patients having visual acuity of counting fingers or less after the age of 30 years. In contrast, dominant *PROM1* mutations in this series were associated with a later onset and a slower decline in visual function, with most patients having visual acuity of at least 1.0 logMAR at the time of presentation. (Three of 6 patients with the dominant variant were in their 50s.) Previously reported^[@zoi190234r19],[@zoi190234r24]^ dominant *PROM1*-related dystrophies (2 variants, c.1117C\>T \[31 patients\] and c.2485G\>A \[1 patient\]) show a similar trend.

![Association of Visual Acuity With Age at Time of Presentation in All *PROM1* Variants Reported to Date\
The mean logMAR score between the right and left eyes is plotted against age. CF indicates counting fingers; HM, hand movements; NPL, no perception of light; and PL, perception of light.](jamanetwopen-2-e195752-g002){#zoi190234f2}

Other ophthalmic features appeared in patients with recessive variations including myopia (4 patients \[21%\]), cataract or history of cataract extraction (8 patients \[42%\]), nystagmus (4 patients \[21%\]), oscillopsia (1 patient \[5%\]), and strabismus (1 patient \[5%\]). There were no consistently associated systemic diseases, although 1 patient had polymyalgia rheumatica and another had psoriasis.

We identified 12 mutations in *PROM1* that may be associated with the disease phenotype, of which 3 were novel ([Table](#zoi190234t1){ref-type="table"}) (eTable 2 in the [Supplement](#note-ZOI190234-1-s){ref-type="supplementary-material"}). All patients with dominant inheritance had the known c.1117C\>T missense variant in *PROM1*. In patients with autosomal recessive disease, 6 variants were truncating variants (3 nonsense and 3 frameshift), 4 were splice site variants, and 1 was a missense variant ([Table](#zoi190234t1){ref-type="table"}). Overall, 7 of 13 patients with recessive disease were homozygous for the identified *PROM1* variant.

Detailed in silico analysis confirmed a pathogenic association with protein function, with all sequence variations having a highly likely pathogenic effect, including the supporting evidence for missense variants from the PolyPhen2, SIFT, and Grantham matrix algorithm scores (eTable 2 in the [Supplement](#note-ZOI190234-1-s){ref-type="supplementary-material"}). The novel variants were not previously reported in the literature, and they were crosschecked against normal variants based on the gnomAD dataset (eTable 2 in the [Supplement](#note-ZOI190234-1-s){ref-type="supplementary-material"}).

A schematic diagram of all *PROM1* mutations reported to date depicts their distribution throughout the protein, with no specific clustering relative to protein domains ([Figure 3](#zoi190234f3){ref-type="fig"}) (eTable 1 in the [Supplement](#note-ZOI190234-1-s){ref-type="supplementary-material"}). Most *PROM1* variants (34 of 41 reported with known inheritance) were found to be recessive (31 of 34: 11 nonsense variants, 9 frameshift variants, 8 splice site variants, and 3 missense variants), whereas only 3 of 34 were dominant (all missense variants). The dominant cases in the current study had the same variant (p.Arg373Cys). The inheritance pattern of reported variant p.Leu3fs\*^[@zoi190234r15]^ remains unclear (excluded from [Figure 3](#zoi190234f3){ref-type="fig"}) (shaded in green in eTable 1 in the [Supplement](#note-ZOI190234-1-s){ref-type="supplementary-material"}). The inheritance pattern of 6 variants is not available in the reporting studies^[@zoi190234r8],[@zoi190234r23]^ (excluded from [Figure 3](#zoi190234f3){ref-type="fig"}) (shaded in yellow in eTable 1 in the [Supplement](#note-ZOI190234-1-s){ref-type="supplementary-material"}).

![Schematic Representation of *PROM1* and Associated Variants\
The *PROM1* protein is shown as a white bar with the respective protein domains depicted in different colors. Recessive variants are shown above, and dominant variants are shown below. Variants from the current study appear in bold, and novel variants appear in red. For splice site and frameshift variants, the arrow indicates the location of the first affected amino acid. Variants without a reliable prediction on the protein (eg, splice site) are marked as p.? with their c. nomenclatures shown underneath.](jamanetwopen-2-e195752-g003){#zoi190234f3}

Discussion {#H1-4-ZOI190234}
==========

In this case-series study, we analyzed the sequence variations in the *PROM1* gene, and we identified 3 novel sequence variations. The types of variant as well as the mode of inheritance were associated with disease phenotype, age at onset of symptoms, and severity of retinal degeneration.

The *PROM1* gene encodes a pentaspan transmembrane domain glycoprotein,^[@zoi190234r29]^ which is expressed ubiquitously in plasma membrane protrusions. It is best known as a surface marker of endothelial progenitor, hematopoietic stem cells (AC133 and CD133) and cancer cells in the central nervous system. In retinal photoreceptors, it has a critical structural role. The protein specifically localizes to membrane protrusions at the base of rod and cone outer segments, where it plays a key role in disc morphogenesis^[@zoi190234r30]^ and subsequent photopigment sorting.^[@zoi190234r31]^ More recently, *PROM1* has been found to be associated with the regulation of photoreceptor autophagy in retinal pigment epithelium cells.^[@zoi190234r32]^

Given the ubiquitous expression of *PROM1*, a remarkable feature of *PROM1*-associated retinal dystrophy in the current series was the absence of an extraocular phenotype. We found no syndromic cases and 2 systemic conditions that were unlikely to be associated with *PROM1* expression. This is in keeping with the current literature, with only 1 study reporting a family with the p.Arg373Cys variant having some subclinical systemic features.^[@zoi190234r33]^ Despite the rarity of an observed extraocular *PROM1* phenotype, we nonetheless need be aware of possible systemic manifestations of the *PROM1* variant when faced with such patients in a genetic clinic. In our study, we noted that, among other ocular features, one-third of patients had myopia. Although it is plausible that *PROM1* is implicated in the pathogenicity of myopia, a more likely explanation is that the myopia is induced by sensory deprivation owing to blurring of vision in patients with *PROM1*sequence variations.

Although previous genetic reports have described numerous *PROM1*-associated retinal dystrophy phenotypes,^[@zoi190234r1],[@zoi190234r2],[@zoi190234r3],[@zoi190234r4],[@zoi190234r5],[@zoi190234r6],[@zoi190234r7],[@zoi190234r8],[@zoi190234r9],[@zoi190234r10],[@zoi190234r11],[@zoi190234r12],[@zoi190234r13],[@zoi190234r14],[@zoi190234r15],[@zoi190234r16],[@zoi190234r17],[@zoi190234r18],[@zoi190234r19],[@zoi190234r20],[@zoi190234r21],[@zoi190234r22],[@zoi190234r23],[@zoi190234r24],[@zoi190234r25]^ in the current study, we found that the morphological phenotype was associated with cone-rod dystrophy in all cases. The main distinction in phenotypes lies between recessive and dominant forms of the disease. The recessive disease was associated with early-onset, severe panretinal degeneration with early central loss of vision, whereas the dominant disease was associated with late-onset dystrophy predominantly involving the macula. In contrast to some previously reported cases,^[@zoi190234r2],[@zoi190234r3]^ we did not find any patients who presented with night vision problems that would suggest early rod-driven functional deficiencies. It is possible, owing to the relatively fast progression of *PROM1*-associated recessive cone-rod dystrophy, that cone and rod dysfunction occur in close succession or simultaneously, making it difficult for patients to distinguish which symptoms (ie, central blurring of vision or nyctalopia) came first. In addition, as the disease progresses, pigmentation indistinguishable from rod-cone dystrophy appears in the retinal periphery.

Our analysis of *PROM1* variations showed that the entire protein is associated with sequence variations, with no major clustering in a domain-dependent manner, suggesting that the entire protein is important to its function. The severe homozygous recessive phenotype is likely associated with null variants that abolish the function of alleles, leading to the absence of *PROM1*. Most frameshift and nonsense variants result in a premature stop codon, leading to a truncated modified RNA that is quickly degraded by nonsense-mediated decay before undergoing translation.^[@zoi190234r2]^ In addition, the missense and splice site variants involved in the recessive disease are likely associated with a null (or loss of function close to null) effect, as evident from the similar phenotypes in our patients with homozygous missense and splice site variants compared with similarly aged patients with truncating mutations. These loss-of-function variants are associated with disorganized optic disc membranes and photoreceptor degeneration, as shown in *PROM1* knockout mice.^[@zoi190234r31]^

In contrast, a milder, dominant phenotype, as observed in our study as well as in most other studies, is associated with a dominant negative effect of a missense variant. This appears to result in a stable variant protein that is associated with the mislocalization of the variant protein. It also appears to interfere with the function of the wild-type protein as well as *CDHR1*and actin,^[@zoi190234r30]^ exerting a dominant negative effect. As cysteine residues are evolutionarily conserved in *PROM1*, it is possible that the addition of another cysteine residue in p.Arg373Cys disrupts disulfide bridges, impairing homophilic protein interactions. The cone-associated phenotype observed in the dominant disease suggests that the dominant variant is preferentially associated with cones. A 2008 study^[@zoi190234r30]^ that implicates *PROM1* in disc morphogenesis used a transgenic mouse model carrying the Arg373Cys variant expressed in rods only under the control of rhodopsin promoter, thereby making it difficult to study the direct effect of this variant in cones. However, in a *PROM1* knockout mouse model,^[@zoi190234r31]^ the null protein impairs disc morphogenesis as well as causes ectopic accumulation of visual pigment in rods and cones. Since cone opsins are more prone to mislocalization than rod opsins,^[@zoi190234r34]^ this could explain why cones become affected first and with greater severity in *PROM1* degeneration. In addition, there is some evidence of a differential distribution of wild-type *PROM1* protein between rods and cones.^[@zoi190234r29],[@zoi190234r35]^ In contrast to rods, the cones' outer segment lamellar membrane is suggested to have a wide distribution of *PROM1* ([Figure 4](#zoi190234f4){ref-type="fig"}). The open lamellar structure of cones' outer segments makes cone proteins more exposed to extracellular space and to interference from other proteins, predisposing cones to premature degeneration.

![Schematic Diagram of Rod and Cone Photoreceptors, Depicting Localization of Wild-Type and Variant *PROM1*\
OS indicates outer segment.](jamanetwopen-2-e195752-g004){#zoi190234f4}

Clarifying the mechanisms underlying *PROM1* degeneration has important implications in the development of potential treatments. Subretinal delivery of adeno-associated viral vector--carrying *PROM1* (2.5 kilobase pairs) to photoreceptors at an early stage of recessive dystrophy could replace the null protein and potentially rescue the phenotype. However, the dominant variant would need to be silenced first, eg, RNA silencing via a mirtron,^[@zoi190234r36]^ followed by a gene replacement therapy of the wild-type protein, ie, block-and-replace therapy. In more advanced instances of disease, where irreversible photoreceptor damage has occurred, restoring sight by optogenetic treatment^[@zoi190234r37]^ may be an alternative therapy. Moreover, the ubiquitous expression of *PROM1* will facilitate the development of in vitro models of *PROM1* gene therapy and related functional assays.

Study Limitations {#H2-3-ZOI190234}
-----------------

This noninterventional case series of 19 patients with *PROM1* variants is limited by the retrospective, uncontrolled nature of the study. In our series and in other reports (with the exception of 2 cases), the dominant disease was caused by a single c.1117C\>T variant. Nonetheless, our study, which, to our knowledge, is the largest reported *PROM1* case series to date, adds substantially to the knowledge and understanding of *PROM1*-related retinal disease and possible future therapies. Further longitudinal studies will shed more light on the natural progression of the disease and the timing of therapeutic interventions.

Conclusions {#H1-5-ZOI190234}
===========

To our knowledge, this is the largest reported case series on *PROM1*-related retinal degeneration to date. This study shows that *PROM1* recessive variants were associated with early-onset, severe retinal degeneration, whereas the c.1117C\>T variant, which was associated with autosomal dominant inheritance, showed a milder, cone-driven phenotype. This clinical and molecular characterization has deepened understanding of the disease and will aid in the design of future randomized clinical trials and therapeutic approaches.

###### 

**eTable 1.** *PROM1* Variants Reported to Date Including Their Respective References

**eTable 2.** Detailed Description of Sequence Variations in *PROM1* in the Series With Predicted Effect on Protein Function

###### 

Click here for additional data file.
